PCSK9 and Hypercholesterolemia: Moreover, clinical trials with proprotein convertase subtilisin/kexin type 9 inhibitors in human subjects with atherosclerotic vascular disease [10, 11] indicate that true normocholesterolemia and hypercholesterolemia in humans should be defined in terms of plasma cholesterol that are much lower than previously accepted.